|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1717 PENNSYLVANIA AVENUE, NW |
Address2 |
|
| City | WASHINGTON |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 24806-12
|
||||||||
|
6. House ID# 336110000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Anders Gilberg |
Date | 1/19/2024 2:45:04 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Telehealth: sent recommendations to the Senate Finance Subcommittee on Healths hearing, Ensuring Medicare Beneficiary Access: A Path to Telehealth Permanency; joined sign-on letter to CMS about reporting a practitioners home address when offering telehealth services.
Medicare payment: Submitted testimony to the House Energy and Commerce Health Subcommittee hearing about Medicare payment, Whats the Prognosis?: Examining Medicare Proposals to Improve Patient Access to Care & Minimize Red Tape for Doctors; joined sign-on letter to Congress with Medicare budget neutrality recommendations; sent letter to the Senate Finance Committees Open Executive Session on the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (S 3430); joined sign-on letter to congressional leadership to avert the scheduled cut to the Medicare conversion factor; sent letter of support for Preserving Seniors Access to Physicians Act of 2023 (HR 6683); joined sign-on letter to congressional leadership about extending the advanced alternative payment model incentive bonus; sent letter to congressional leadership with recommendations for Medicare payment reform for 2024.
MIPS: Joined sign-on letter in support of the SURS Extension Act (HR 5935).
Rural Healthcare: Responded to House Ways and Means RFI on improving healthcare in rural and underserved areas.
No Surprises Act: submitted comments to HHS on proposed No Surprises Act rule on independent dispute resolution operations; submitted recommendations to House Ways and Means Hearing, Reduced Care for Patients: Fallout From Flawed Implementation of Surprise Medical Billing Protections.
Discrimination on the Basis of Disability: Submitted comments to HHS in response to their proposed rule about discrimination on the basis of disability.
Laboratory Developed Tests: submitted comments to the FDA in response to their rulemaking on laboratory developed tests (LDT); joined sign-on letter to extend the comment deadline for FDAs LDT rulemaking; joined sign-on letter to Congress to urge FDA to pause LDT rulemaking and work on legislation.
Electronic Funds Transfer Fees: Supported the No Fees for EFTs Act (HR 6487).
Prior Authorization: Included support for the reintroduction of the Improving Seniors Timely Access to Care Act in our legislative recommendations to congressional leadership for 2024.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anders |
Gilberg |
|
|
|
Claire |
Ernst |
|
|
|
James |
Haynes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Telehealth: sent recommendations to the Senate Finance Subcommittee on Healths hearing, Ensuring Medicare Beneficiary Access: A Path to Telehealth Permanency; joined sign-on letter to CMS about reporting a practitioners home address when offering telehealth services.
Medicare payment: Submitted testimony to the House Energy and Commerce Health Subcommittee hearing about Medicare payment, Whats the Prognosis?: Examining Medicare Proposals to Improve Patient Access to Care & Minimize Red Tape for Doctors; joined sign-on letter to Congress with Medicare budget neutrality recommendations; sent letter to the Senate Finance Committees Open Executive Session on the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (S 3430); joined sign-on letter to congressional leadership to avert the scheduled cut to the Medicare conversion factor; sent letter of support for Preserving Seniors Access to Physicians Act of 2023 (HR 6683); joined sign-on letter to congressional leadership about extending the advanced alternative payment model incentive bonus; sent letter to congressional leadership with recommendations for Medicare payment reform for 2024.
MIPS: Joined sign-on letter in support of the SURS Extension Act (HR 5935).
Rural Healthcare: Responded to House Ways and Means RFI on improving healthcare in rural and underserved areas.
No Surprises Act: submitted comments to HHS on proposed No Surprises Act rule on independent dispute resolution operations; submitted recommendations to House Ways and Means Hearing, Reduced Care for Patients: Fallout From Flawed Implementation of Surprise Medical Billing Protections.
Discrimination on the Basis of Disability: Submitted comments to HHS in response to their proposed rule about discrimination on the basis of disability.
Laboratory Developed Tests: submitted comments to the FDA in response to their rulemaking on laboratory developed tests (LDT); joined sign-on letter to extend the comment deadline for FDAs LDT rulemaking; joined sign-on letter to Congress to urge FDA to pause LDT rulemaking and work on legislation.
Electronic Funds Transfer Fees: Supported the No Fees for EFTs Act (HR 6487).
Prior Authorization: Included support for the reintroduction of the Improving Seniors Timely Access to Care Act in our legislative recommendations to congressional leadership for 2024.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Claire |
Ernst |
|
|
|
Anders |
Gilberg |
|
|
|
James |
Haynes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |